- VimRx Pharmaceuticals Inc., Stamford, Conn., said Johns HopkinsUniversity has gained approval to conduct the Phase I/II HIV/AIDStrial of oral dosing of hypercin, a naturally occurring antiviraltreatment.- Xytronyx Inc., San Diego, said that Colgate Pharmaceuticals istest-marketing Xytronyx's PerioGard periodontal tissue monitorkit in Canada.- North American Biologicals Inc., Miami, said it plans to builda biopharmaceutical manufacturing facility, where the company willprocess raw human specialty plasma from its collection centers intoimmune globulin therapeutics.- ChemTrak Inc., Sunnyvale, Calif., said it was awarded a $500,000Small Business Innovation Research Phase II grant for researchinto high-density lipoprotein testing. The grant came from theNational Heart, Lung, and Blood Institute of the NationalInstitutes of Health.- Mallinckrodt Medical Inc., St. Louis, said it received FDAapproval to market OctreoScan, a kit for the preparation ofIndium-111, which is a radiopharmaceutical that localizes andbinds to specific receptors on certain cancer tumors.- Ixsys Inc., San Diego, obtained an exclusive license from theScripps Research Institute for a monoclonal antibody that hasdemonstrated potential for the treatment of malignant tumors.The company said it intends to develop a humanized antibodyto treat cancer and other diseases.- HemaSure Inc., Marlborough, Mass., announced a collaborationwith the German Red Cross Blood Transfusion Service to expeditedelivery of the company's LeukoVir Filter, which is designed foruse in the viral inactivation of plasma for transfusion.

(c) 1997 American Health Consultants. All rights reserved.